SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19

Nina Kreuzberger, Caroline Hirsch, Khai Li Chai, Vanessa Piechotta, Sarah J. Valk, Lise J. Estcourt*, Susanne Salomon, Eve Tomlinson, Ina Monsef, Erica M. Wood, Cynthia So-Osman, David J. Roberts, Zoe McQuilten, Nicole Skoetz

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

34 Citations (Scopus)


Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To assess whether SARS-CoV-2-neutralising mAbs are effective and safe for treating patients with COVID-19 in comparison to an active comparator, placebo or no intervention, and to maintain the currency of the evidence, using a living systematic review approach. A secondary objective is to track newly developing SARS-CoV-2-targeting mAbs from first tests in humans onwards.

Original languageEnglish
Article numberCD013825
JournalThe Cochrane database of systematic reviews
Issue number1
Publication statusPublished - 15 Jan 2021
Externally publishedYes

Bibliographical note

Funding Information:
The research was supported by NHS Blood and Transplant and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

Funding Information:
NK: is funded by the Federal Ministry of Education and Research, Germany (NaFoUniMedCovid19, funding number: 01KX2021; part of the project "COVIM", which was paid to the institution).

Funding Information:
The research was part of a project supported by the German Federal Ministry of Education and Research (NaFoUniMedCovid19, funding number: 01KX2021; part of the project "COVIM"). The contents of this document reflect only the authors' views and the German Ministry is not responsible for any use that may be made of the information it contains.

Publisher Copyright:
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.


Dive into the research topics of 'SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19'. Together they form a unique fingerprint.

Cite this